DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
HUJ591 111IN
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
HUJ591 111IN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STX-100
2
Antibody
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis
Integrin alpha-V/beta-6 inhibitor
STX-100
×
Maximum Phase:
2
First Approval:
None
UNII:
JD43Y6YF3N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEFIBAZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Clumping factor A inhibitor
TEFIBAZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
SBO7Q9G95R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LERONLIMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Colorectal Neoplasms; Graft vs Host Disease; HIV Infections; Neoplasms; Non-alcoholic Fatty Liver Disease; Severe Acute Respiratory Syndrome
C-C chemokine receptor type 5 antagonist
LERONLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Y1J4NP8FF0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUROVATAMIG
2
Antibody
Unknown
Unknown
Unknown
Leukemia, Biphenotypic, Acute; Neoplasms
Unknown
SUROVATAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RADEMIKIBART
2
Antibody
Unknown
Unknown
Unknown
Inflammation
Unknown
RADEMIKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XTL-6865
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
XTL-6865
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY-2382770
2
Antibody
Investigational
Unknown
Unknown
Diabetic Nephropathies
Transforming growth factor beta-1 inhibitor
LY-2382770
×
Maximum Phase:
2
First Approval:
None
UNII:
9TS3G2M6LS
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PORUSTOBART
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
PORUSTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAXMOTABART
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
CAXMOTABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATIGOTATUG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms; Small Cell Lung Carcinoma
Fucosyl-GM1 binding agent
ATIGOTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CALOTATUG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
CALOTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACTOXUMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Toxin A inhibitor
ACTOXUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G3LU5LC5SX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMIVALIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Programmed cell death protein 1 inhibitor
PIMIVALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
MA05AF40UO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HU3S193
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Lewis Y antigen binding agent
HU3S193
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADINTREVIMAB
2
Antibody
Investigational
Unknown
Unknown
COVID-19; Severe Acute Respiratory Syndrome
Spike glycoprotein inhibitor
ADINTREVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
054Q5D7VZI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IFINATAMAB
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
IFINATAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4K42H9EDW7
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BW250/183
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BW250/183
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TECHNETIUM (99MTC) PINTUMOMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TECHNETIUM (99MTC) PINTUMOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma
Tumor necrosis factor receptor superfamily member 5 antagonist
LUCATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
P0EP9VFC4R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUTACIMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SUTACIMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VILAMAKITUG
2
Antibody
Unknown
Unknown
Unknown
Inflammation; Pancreatic Neoplasms
Unknown
VILAMAKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UNASNEMAB
2
Antibody
Investigational
Unknown
Unknown
Spinal Cord Injuries
Repulsive guidance molecule A inhibitor
UNASNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XB2155292Y
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REMTOLUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic; Arthritis, Rheumatoid
Interleukin 17A inhibitor
REMTOLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1V8WRH3RVX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZINLIRVIMAB
2
Antibody
Unknown
Unknown
Unknown
HIV Infections
Envelope protein inhibitor
ZINLIRVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
L98LJF15I9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NADECNEMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
NADECNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1AIQ625714
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CANTUZUMAB MERTANSINE
2
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
CANTUZUMAB MERTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
7Z7EUX7R6M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DIBOTATUG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
DIBOTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
URTOXAZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Shiga toxin subunit B inhibitor
URTOXAZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
232D35B3NT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VERZISTOBART
2
Antibody
Unknown
Unknown
Unknown
Melanoma; Neoplasms; Carcinoma, Merkel Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Urinary Bladder Neoplasms
Unknown
VERZISTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUGEMALIMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Hodgkin Disease; Lymphoma; Small Cell Lung Carcinoma; Adenocarcinoma; Esophageal Neoplasms; Granuloma, Lethal Midline; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms
Programmed cell death 1 ligand 1 binding agent
SUGEMALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
90IQR2I6TR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XIRESTOMIG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
XIRESTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMNESKIBART
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
IMNESKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINAVONKIBART
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
LINAVONKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIBAVADEMAB
2
Antibody
Investigational
Unknown
Unknown
Lipodystrophy, Congenital Generalized
Leptin receptor agonist
MIBAVADEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
PHL2UDY3AB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
22
23
24
25
26
27
28
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA